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Abstract: Purpose: The purpose of this study was to assess differences in the physiological profiles of
completers vs. non-completers following a structured exercise programme (SEP) and the ability to
predict non-completers, which is currently unknown in this group. Methods: Sixty-nine patients
met the Fukuda criteria. Patients completed baseline measures assessing fatigue, autonomic nervous
system (ANS), cognitive, and cardiovascular function. Thirty-four patients completed a home-based
SEP consisting of 10–40 min per day at between 30 and 80% actual HR max. Exercise intensity and
time was increased gradually across the 16 weeks and baseline measures were repeated following
the SEP. Results: Thirty-five patients discontinued, while 34 completed SEP. For every increase
in sympathetic drive for blood pressure control as measured by the taskforce, completion of SEP
decreased by a multiple of 0.1. For a 1 millisecond increase in reaction time for the simple reaction
time (SRT), the probability for completion of SEP also decreases by a multiple of 0.01. For a one
beat HRmax increase, there is a 4% increase in the odds of completing SEP. Conclusion: The more
sympathetic drive in the control of blood vessels, the longer the reaction time on simple visual stimuli
and the lower the HRmax during physical exercise, then the lower the chance of SEP completion in
ME/CFS.
Keywords: myalgic encephalomyelitis; chronic fatigue syndrome; autonomic nervous system;
exercise; chronotropic intolerance; maximal heart rate; brain fog
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1. Introduction
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex condition
characterised by intense debilitating fatigue after physical activity. Individuals self-report symptoms
including musculoskeletal pain, sleep disturbance, headaches, impairments in concentration and
short-term memory [1]. Accumulating evidence suggests that the cardiovascular system may be
compromised in individuals suffering with ME/CFS, along with reports of autonomic dysfunction [2],
impaired heart rate, blood pressure regulation, and also impaired heart conduction [3]. Disturbance in
response to physical exercise in ME/CFS is characterized by some patients as chronotropic intolerance,
which is manifested by a lower maximal heart rate (HRmax) of less than 85% of age-predicted maximal
exercise during a cardiopulmonary exercise test [4,5].
Previous studies have indicated the relationship between autonomic disturbance and cognitive
dysfunction in ME/CFS [6]. Moreover, a decline in cognitive function has been noted after
orthostatic stress, which is a provocative test for autonomic nervous system responsiveness [7].
Autonomic nervous system dysfunction is one of the most widely described parts of ME/CFS
pathomechanisms [8]. Autonomic dysfunction could be related to a decrease in processing speed
in ME/CFS [7]. Autonomic nervous system function was measured non-invasively using heart rate
variability (HRV) as an indicator of cardiac autonomic innervation [7]. Processing speed could be
measured by a simple reaction time test. Similar protocols based on this test have been applied in other
patient groups [9]. The authors of meta-analysis describing pathological changes in autonomic cardiac
innervation in ME/CFS suggested that the resting sympathetic hyperactivity, indicated by changes in
HRV and blood pressure variability (BPV) might lead to a decrease in HRmax in ME/CFS patients [4].
Presumably, chronic sympathetic overactivity might lead to the downregulation of autonomic nervous
system receptors and therefore lead to a decrease in HRmax. In recent years, treatment for ME/CFS has
been largely focussed upon graded exercise therapy (GET) [10]. It was reported that 90% of examined
ME/CFS patients suffer from post exertional malaise (PEM) [11]. Exacerbation of symptoms due to the
physical or mental exercise in ME/CFS patients may potentially explain the statistically non-significant
long-term effects of physical exercise programs on fatigue and disability compared to patients allocated
to receiving standard medical care [12,13].
Exercise adherence is an important part of exercise prescription. PEM is a key symptom in
individuals with ME/CFS [11]. It is important to consider this key symptom when prescribing an
exercise programme for this population, as exercise may provoke these symptoms and as such decrease
exercise adherence. It is important to note that in the PACE trial, exercise adherence was not directly
measured, and only attendance was measured [14,15]. It was clear after 12 months of completing
exercise prescription that there were minimal changes in fitness between the groups [15]. The lack of
changes in fitness may suggest that there was a lack of adherence to the exercise programme; however,
this was not directly reported [14,15]. The CONSORT statement on harms notes “it is important to
report participants who are non-adherent or lost to follow up, because their actions may reflect their
inability to tolerate the intervention” [16].
The purpose of this study is to address whether exercise adherence is a problem in this group of
individuals and to gain an understanding of whether there is an underlying difference in physiology
of those who complete the exercise trial compared with those who do not. We believe this is the first
study of its kind and is of significant importance for this group.
2. Experimental Section
2.1. Participants
The study design was an exercise intervention study. The trial included two testing visits, once at
baseline, and one post exercise intervention. The study was approved by the Ethics Committee,
Ludwik Rydygier Memorial Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University,
Torun (KB 332/2013, date of approval: 25 June 2013); and written informed consent was obtained
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from all participants. Power calculation was based on the effect size of difference in HRpeak score in
completers vs. non-completers using the pwr package in R environment. Assuming Cohen’s d = 0.68,
the estimated power was 0.64.
Recruitment and Eligibility
ME/CFS patients were included if they met the diagnostic criteria of the Fukuda case definition [17].
Initially, 1400 volunteers were assessed for eligibility in the trial, with 1308 being excluded. This left
69 individuals who met the trial inclusion criteria. However, only 53 patients undertook the
structured exercise programme (SEP) protocol because 16 patients resigned from undertaking baseline
cardiopulmonary exercise test (CPET). Thirty-four patients completed the protocol and n = 19 dropped
out due to a reported severe post-exertional malaise (PEM) reaction to SEP (Figure 1).
Figure 1. CONSORT-type flow diagram.
2.2. Measures
2.2.1. Fatigue Assessment Tools
The Chalder Fatigue Questionnaire (CFQ) was administered to assess fatigue severity.
The questionnaire consists of 11 questions and is scored using a Likert scale of 0–3 (whereby 0
is the lowest, and 3 is the highest). Total or global score ranges from 0 to 33. The questionnaire is further
split into two domains, physical fatigue (Q1–7) and psychological fatigue (Q8–11), which allows for
the severity of physical and psychological fatigue to be assessed individually. Higher scores indicate
higher symptom severity. The scale was validated in CFS patients [18].
The Fatigue Severity Score (FSS) contains 9 items examining the severity of factors related to
fatigue during the past week. Scores range from 1 to 7, whereby 1 indicates strong disagreement and 7
strong agreement, with a higher score indicating a higher severity of fatigue [19].
The Fatigue Impact Scale (FIS) contains 40 items, scores range from 0 (no problem) to 4
(extreme problem) and is split into three domains of functioning; cognitive, physical and psychosocial.
The higher the score, the more severe the symptoms. The total score ranges from 0 to 160 but can be
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divided into the three separate domains [20]. All questionnaires were administered at baseline and
post-SEP intervention.
2.2.2. Cognitive Function Measurement
Cognitive function was assessed using the computerized battery test described in more detail by
Zalewski et al. (2020)—Test Sprawności Operacyjnej (TSO) (software version 4.6.0.44744, Speednet sp.
z. o. o., more information available at http://www.biostat.com.pl/news/nowa_aplikacja_tso_stat_-181.
php). TSO has been previously described in detail [21]. In brief, the simple reaction time (SRT) subtest
involves the response to simple visual stimuli. Scores from the first attempt at the test after a short
introduction were analysed.
2.2.3. Autonomic Nervous System Measurement
Autonomic nervous system functioning was measured with Task Force Monitor—TFM
(CNS Systems, Gratz, Austria) before more strenuous examinations to avoid confounding measured
parameters. Signals from three-channel electrocardiogram (ECG) and continuous blood pressure
monitoring (contBP with periodically cross-checked oscillometric blood pressure measurements)
is analysed using the adaptive autoregressive model [22]. The TFM provides spectral analysis of
blood pressure variability as indicators for sympathetic: low frequency (LF) and parasympathetic:
high frequency (HF) regulation examination [23,24].
2.2.4. Cardiopulmonary Exercise Testing
In the presence of a physician, the patients undertook a cardiopulmonary exercise test (CPET) using
the Bruce protocol (Cardiovit CS-200 Ergo-Spiro, Schiller AG, Baar, Switzerland) at baseline [25,26].
A trained technician provided brief instruction and advised that the test would end voluntarily at the
moment of subjective full exertion, or at any other time point, or at the command of the physician,
using the guidelines for safe exercise testing by the American College of Sports Medicine [27].
As analysis of the VO2 plateau was omitted, a suffix “peak” is added to all variables measured during
maximal workload during CPET. Heart rate (HR), oxygen consumption rate (VO2), carbon dioxide
production rate (VCO2), minute ventilation (VE) and respiratory exchange ratio (RER (VCO2:VO2))
were measured to assess cardiopulmonary fitness at baseline (before SEP intervention) [25,26].
Chronotropic intolerance was defined if an actual HRpeak reached during CPET was lower than
85% of predicted maximal heart rate based on 220-age equation [5].
2.2.5. Body Composition Analysis
To measure body composition a multi-frequency bioelectrical impedance analyser
(Tanita MC-180MA Body Composition Analyzer, Tanita UK Ltd.) was used to assess weight (kg),
fat mass (%), fat-free mass (%) and total body water (%). BMI (kg/m2) was automatically calculated by
entering the subject’s height (cm), age (years) and gender.
2.3. Intervention
The SEP has been previously described in detail [21]. In brief, the programme consisted of a
prescribed 16-week multimodal home exercise programme for 5 days a week, with time (10–40 min) and
intensity (30–80% HRpeak) increasing gradually across the time period. Patients were equipped with
heart rate monitors (Beurer PM 25) to help them in sustaining the recommended heart rate. HR intensity
was individually prescribed based on the actual HRpeak achieved during the CPET. However, only 1
patient actually reached 80% of HRpeak during the last training sessions. Thirty-two patients reached
70%HRpeak, and 1 patient underwent last training sessions at 60%HRpeak. Participants were
encouraged to undertake walking; however, cycling and swimming were allowed on a patients’ request.
All subjects chose walking. Every week, telephone calls were made to resolve potential problems with
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compliance and to ensure patients were satisfied with the protocol. Patients underwent a minimum of
80 training sessions. The mean compliance rate was 80%. All of the analysed patients’ compliance
rates were above 60%, which was a threshold value.
2.4. Statistical Analyses
Shapiro–Wilk test and histograms were used to test the assumption of normality. Mann–Whitney U
or independent T-tests were used to examine between-group differences (completers vs. non-completers)
depending on assumptions met. Benjamini–Hochberg adjusted p value was chosen to control
for false discovery rate (FDR) in between-group comparisons. An online calculator available at
https://www.sdmproject.com/utilities/?show=FDR was used to make a correction for the number of
between-group comparisons made.
To predict SEP completion in examined patients, logistic regression model using glm function
was applied in R. One cell with a lack of data in one of predictors was replaced with the mean value
from the subgroup. In addition, 95% confidence intervals for log-likelihoods and odds ratios were
calculated (confit function). DescTools package was used to calculate pseudo R2 for the model [28].
Dotwhisker plots were used to visualize odds ratios and confidence intervals [29]. Fisher’s exact test
was applied to analyse the association between the presence of chronotropic intolerance with the
non-completion of SEP.
3. Results
3.1. Comparison of Completers vs. Non-Completers before SEP
Thirty-four patients completed SEP while 35 did not. Data from n = 69 patients were analysed,
except for CPET, where n = 19 in the non-completers group underwent this examination. There were 20
females in SEP completers subgroup and 21 in non-completers. A comparison of the body composition
and age of completers vs. non-completers before SEP is presented in Table 1. No significant difference
was observed in age, BMI, free fat mass (FFM) or in fat percentage.
Table 1. Comparison of completers vs. non-completers in body composition before structured exercise
programme (SEP).
Variable Mean (SD)Non-Completers (n = 35) Mean (SD) Completers (n = 34) p Value FDR Adjusted p Value
Age (years) 39.6 (9) 37.06 (7.9) 0.25 0.57
BMI (kg/m2) 24.02 (3.5) 24.52 (3.2) 0.54 0.86
FFM (kg) 53.76 (11) 54.45 (9.7) 0.78 0.99
Fat (%) 24.2 (7) 25.04 (6.6) 0.61 0.92
BMI—body mass index, FFM—free-fat mass.
A comparison of the fatigue of completers vs. non-completers before SEP is presented in Table 2.
No significant difference was observed in fatigue before SEP in completers vs. non-completers.
Table 2. Comparison of completers vs. non-completers in fatigue before SEP.
Variable Mean (SD)Non-Completers (n = 35) Mean (SD) Completers (n = 34) p Value FDR Adjusted p Value
CFQ (points) 24.54 (3.9) 26.12 (3.5) 0.08 0.38
FSS (points) 48.74 (8.7) 48.91 (8.9) 0.94 0.99
FIS (points) 90.91 (27.7) 93.59 (24.9) 0.67 0.96
CFS—Chronic Fatigue Questionnaire, FSS—Fatigue Severity Scale, FIS—Fatigue Impact Scale.
The comparison of autonomic nervous system functioning before SEP is presented in Table 3.
Non-completers had significantly higher LFnu-sBP (46.99 (13.2)% vs. 37.14 (12.1)%, Z = 2.81, p = 0.005,
r = 0.34) and reaction time in the SRT.1 (647.91 (174.1) ms vs. 547.09 (162.6) ms, Z = 3.11, p = 0.002,
r = 0.38). However, the results are not significant after FDR correction.
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Table 3. Comparison of completers vs. non-completers in autonomic nervous system and cognitive
functioning before SEP.
Variable
Mean (SD)
Non-Completers
(n = 35)
Mean (SD)
Completers
(n = 34)
p Value FDR Adjustedp Value
LFnu-RRI (%) 51.62 (19) 56.81 (14.9) 0.21 0.57
HFnu-RRI (%) 48.38 (19) 43.19 (14.9) 0.21 0.57
LF/HF-RRI 1.55 (1.3) 1.91 (2) 0.40 0.69
LF/HF 1.42 (0.8) 1.53 (1.3) 0.82 0.99
LFnu-dBP (%) 54.24 (14.9) 50.06 (14.4) 0.24 0.57
HFnu-dBP (%) 14.23 (11.4) 13.73 (9.4) 0.78 0.99
LFnu-sBP (%) 46.99 (13.2) 37.14 (12.1) 0.005 0.08
HFnu-sBP (%) 16.61 (10) 16.46 (11.6) 0.95 0.99
SRT.1 mean
reaction time (ms) 647.91 (174.1) 547.09 (162.6) 0.002 0.07
LFnu-RRI (%)—low-frequency normalized units of R-R interval, HFnu-RRI (%)—high-frequency normalized units
of R-R interval, LF/HF-RRI—ratio of LF to HF of R-R interval, LF/HF—ratio of LF-dBP to HF-RRI, LFnu-dBP
(%)—low-frequency normalized units of diastolic blood pressure, HFnu-dBP (%)—high-frequency normalized units
of diastolic blood pressure, LFnu-sBP (%)—low-frequency normalized units of systolic blood pressure, HFnu-sBP
(%)—high-frequency normalized units of systolic blood pressure, SRT.1 mean reaction time (ms)—mean reaction
time in the first attempt to Simple Reaction Time test.
Nineteen non-completers underwent CPET before SEP. No significant differences between groups
were found in CPET parameters during AT (Table 4).
Table 4. Comparison of completers vs. non-completers before SEP in cardiopulmonary exercise test
(CPET) parameters during AT.
Variable
Mean (SD)
Non-Completers
(n = 19)
Mean (SD)
Completers
(n = 34)
p Value FDR Adjustedp Value
VO2 AT
[mL/kg/min] 21.89 (5.9) 21.86 (4.8) 0.99 0.99
VCO2 AT
[mL/kg/min] 21.21 (6.7) 21.36 (4.9) 0.93 0.99
RER AT 0.96 (0.1) 0.98 (0) 0.95 0.99
VE AT [mL/kg/min] 602.84 (190.8) 579.86 (128.8) 0.24 0.57
HR AT [bpm] 136.00 (22.5) 144.21 (16.4) 0.14 0.57
Load AT [W] 102.28 (22.3) 99.26 (44.4) 0.31 0.60
sBP AT [mmHg] 161.72 (51.5) 167.18 (23.8) 0.99 0.99
dBP AT [mmHg] 81.39 (24.1) 88.59 (14.9) 0.55 0.86
VO2/kg AT (ml/min/kg)—oxygen consumption during anaerobic threshold, VCO2/kg AT (ml/min/kg)—carbon
dioxide production during anaerobic threshold, RER AT—ratio of VCO2 to VO2 during anaerobic threshold,
VE/kg AT [ml/kg/min]—minute ventilation during anaerobic threshold, HR AT [bpm]—heart rate during anaerobic
threshold, Load AT [W]—load during anaerobic threshold, sBP AT [mmHg]—systolic blood pressure during
anaerobic threshold, dBP AT [mmHg]—diastolic blood pressure during anaerobic threshold.
Chronotropic intolerance was noted in four patients in the completers group (11.76%) compared
to seven patients (20%) in the non-completers group (p = 0.04). Non-completers had significantly lower
RERpeak (1.08 (0.1) % vs. 1.15 (0.1), Z = −2.12 p = 0.03, r = −0.29. However, this comparison was not
significant after FDR correction (Table 5). Nine out of 19 patients in the non-completers group (47.37%)
did not reach RERpeak ≥ 1.1, while 6 patients from 34 (17.65%) in the completers group did not reach
this threshold.
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Table 5. Comparison of completers vs. non-completers before SEP in CPET parameters during
maximal exercise.
Variable
Mean (SD)
Non-Completers
(n = 19)
Mean (SD)
Completers
(n = 34)
p Value FDR Adjustedp Value
VO2peak
[mL/min/kg] 26.33 (7.4) 29.49 (6.3) 0.07 0.38
VCO2peak
[mL/min/kg] 29.41 (9.8) 34.04 (7.7) 0.06 0.38
RERpeak 1.08 (0.1) 1.15 (0.1) 0.03 0.33
VEpeak
[mL/kg/min] 885.09 (318.8) 968.35 (239.6) 0.29 0.60
HRpeak [bpm] 166.39 (25) 182.35 (21.9) 0.06 0.38
Load peak [W] 119.84 (47.6) 132.94 (34.6) 0.26 0.57
sBPpeak [mmHg] 191.58 (35.0) 180.94 (26.7) 0.22 0.57
dBPpeak [mmHg] 90.53 (13.5) 90.65 (11.1) 0.97 0.99
VO2/kg peak (ml/min/kg)—oxygen consumption during maximal intensity exercise, VCO2/kg peak
(ml/min/kg)—carbon dioxide production during maximal intensity exercise, RER peak—ratio of VCO2 to VO2 during
maximal intensity exercise, VE/kg peak [ml/kg/min]—minute ventilation during maximal intensity exercise, HR peak
[bpm]—heart rate during maximal intensity exercise, Load peak [W]—load during maximal intensity exercise,
sBP peak [mmHg]—systolic blood pressure during maximal intensity exercise, dBP peak [mmHg]—diastolic blood
pressure during maximal intensity exercise.
3.2. Predictors of SEP Completion
Table A1 presents the results of the logistic regression model predicting SEP completion.
For normalized low frequency systolic blood pressure unit increase, the probability of the completion
of SEP decreases by a multiple of 0.11. For the increase in the reaction time in the first attempt to SRT,
the probability of the completion of SEP decreases by a multiple of 0.01. For a one beat per minute
more of heart rate during maximal physical exercise, an increase about 4% in the odds of completing
SEP is expected (AIC = 54.07, BIC = 61.96, Tjur R2 = 0.38) (Figure 2).
Figure 2. Odds ratio for SEP completion. Horizontal axis refers to odds ratio. Dots denote odds ratio,
while horizontal lines nearby dots denote −95 and 95% of odds ratio confidence intervals.
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4. Discussion
This study demonstrates that the more the sympathetic drive in the control of blood vessels as
measured by TFM (low frequency systolic blood pressure), the longer the reaction time on simple
visual stimuli measured by simple reaction time test reflecting slower cognitive functioning and the
lower maximal heart rate during physical exercise, then the less chance there is of SEP completion.
Moreover, chronotropic intolerance occurred more frequently in non-completers than in completers.
However, what should be underlined is that we have noted a considerable withdrawal rate (35 from 69
patients). Sixteen resigned from CPET during baseline, due to the fear of exacerbating symptoms of
post-exertional malaise. Of those remaining, 19 undertook the baseline CPET but dropped out of the
SEP due to adverse effects, leaving 34 who completed the SEP.
4.1. Withdrawal Rate
Whilst withdrawals are completely normal during supervised exercise programmes,
when comparing this rate in the current study (23% pre CPET testing, 36% after CPET testing)
to those in previously reported studies within ME/CFS, it is interesting to note that this is substantially
larger than that evidenced in the GET trial (6%) [10], and the GETSET study (12 participants, 6%) of 211
participants [30]. In the current study, the mean score of CFQ before SEP 26.12, which is comparable to
both the GET group in the PACE trial (28.2 points) [31] and for the GET group in the GETSET trial
(26.3) [10]. In addition, we found no significant differences between our groups of completers and
non-completers. Therefore, higher dropout rate in the above study is not explained by greater fatigue
before physical exercise programmes. It could be speculated that the above sample suffered from
more frequent and/or intense PEM; however, it was not measured by any scale. Therefore, no strong
conclusions could be drawn based on dropout rate noted in the above study.
4.2. Differences between SEP Completers and Non-Completers
Respiratory exchange ratio is one of the best indicators of effort during physical exercise.
Maximal effort is indicated by RER ≥ 1.1 [27]. In the above study, SEP non-completers were
characterized by lower RER max than completers. In contrast with the above findings, all 22
examined ME/CFS patients’ RER max scores were high (≥1.1) [32]. Moreover, RER max was reproduced
24 h during the following CPET test [32]. Moreover, Oosterwijck et al. reported that the mean RER
max as 1.25 (0.98) in 22 women with ME/CFS [33], which was higher than RER max in a control
group consisting of sedentary subjects (mean 0.92 (0.11). In another study, patients were divided into
three subgroups according to symptom severity (severe, moderate and mild) and underwent 2-day
CPET protocol [34]. RER max was 1.08 (0.09) in the severe group, 1.09 (0.09) in the moderate and 1.13
(0.11) in the mild subgroups in the first CPET. In our study, non-completers also reached a mean of
1.08 RER max, similarly to the most severe group in van Campen et al. The Authors [34] suggests
that for patients in a severe group, skeletal muscle exhaustion might occur faster than limitations of
central hemodynamic and ventilatory origins. In line with that explanation, we also speculate that
non-completers in the current study perceived more intense adverse effects during physical exercise
and therefore ended more quickly.
What is interesting is that we have noted no statistically significant results in VO2max between
completers and non-completers. However, the observed differences suggest that clinically significant
better VO2max in completers vs. non-completers, according to the definition of minimum clinically
important difference between CFS and controls, is of 1.1 mL/kg/min [35]. Mitochondrial dysfunction is
suggested as one of the main factors in ME/CFS pathomechanism [36]. In EACPR/AHA, the Scientific
Statement suggests that the measurement of the ratio of maximal cardiac output to VO2max in patients
with suspected mitochondrial myopathy is useful in diagnosis [37]. Therefore, we suggest that further
studies on ME/CFS should focus on including the wide assessment of multiple systems functioning in
response to physical exercise.
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4.3. Predictors of SEP Completion
This study is the first to analyse the predictors of completion of a multimodal supervised exercise
program in ME/CFS patients. It is evident in the examined sample that the greater sympathetic drive
in control of blood vessels, the longer reaction time on simple visual stimuli, and lower maximal
heart rate levels found during physical exercise, are linked to lower chance of SEP completion.
Recent meta-analysis has described disturbance in the autonomic control over heart rate in ME/CFS;
however, it is important to be able to distinguish whether this involves all individuals with diagnosed
ME/CFS or whether this is indeed a subset of those individuals. It is becoming increasingly evident that
ME/CFS participants are characterized by lower maximal heart rate during physical exercise sessions [4].
This phenomenon is described as chronotropic intolerance [5]. In our current study, it can be seen
that completers demonstrated a peak HR of 93% of age predicted max, whilst the non-completers
demonstrated a peak HR of 86%, therefore demonstrating that the non-completers showed evidence of
chronotropic intolerance. It has also been demonstrated that there is aa disturbance in the autonomic
control of blood vessels, which may be related to a worsening response to physical exercise in ME/CFS
patients. During physical exercise, blood is redistributed to supply working muscles. However,
a recent study found endothelial dysfunction in ME/CFS [38]. Taking into account methodological
problems of non-invasive autonomic nervous system function monitoring, low frequency systolic
blood pressure might be a more precise indicator of sympathetic activity than low frequency of heart
rate [39–41].
Brain fog/cognitive function disturbance is one of the most prominent symptoms in patients with
ME/CFS, occurring in 85–95% [42,43]. In the current study, those who withdrew from the supervised
exercise displayed worse cognitive function than those who completed the exercise, which indicates
that cognitive dysfunction might coexist with a poor response to physical exercise in ME/CFS subjects.
Coexistence of autonomic disturbance and cognitive dysfunction in ME/CFS was noted in previous
studies [7,8]. On the other hand, it might be speculated that nervous system disturbances might play a
role in PEM pathomechanism. Therefore, we suggest including both cognitive and autonomic along
with PEM assessment into ME/CFS patients routine diagnosis.
4.4. Study Limitations
We have noted a considerable withdrawal rate (35 from 69 patients). Sixteen patients resigned from
CPET during baseline and therefore we were unable to incorporate this subgroup in all comparisons.
Moreover, in the above study, PEM was not measured. Due to the relatively small sample size,
results on differences SEP completers and non-completers should be replicated in further studies.
A potential future research study should incorporate a questionnaire assessing PEM in ME/CFS patients
undergoing aerobic exercise program. Moreover, the effects of personalizing the intensity of an exercise
program based on CPET result and PEM should be examined.
5. Conclusions
In conclusion, this study is the first to demonstrate possible physiological reasons for participant
withdrawal from studies which use the NICE endorsed physical exercise programme. However, due to
the small sample size in this study, this study should be replicated.
This study demonstrated that structured exercise programmes may not be suitable for all
individuals with ME/CFS. It is apparent that there may be a subgroup of individuals who have
chronotropic intolerance, as demonstrated through a single CPET test. Further studies should focus on
whether these individuals should avoid supervised exercise programmes as well as elucidating other
important markers such as CPET testing results, autonomic and cognitive function, amongst others
which may further help in personalizing therapy for ME/CFS subgroups.
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Appendix A
Table A1. Logistic regression coefficients predicting SEP completion.
Variable Estimate −95% CI 95% CI z Value Pr(>|z|)
(Intercept) 3.15 −3.07 9.38 0.99 0.32
LFnu sBP −0.12 −0.20 −0.04 −2.92 0.003
SRT.1 reaction time −0.01 −0.01 −0.0008 −2.29 0.02
HRmax baseline
CPET 0.03 0.005 0.06 2.26 0.02
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